EN DE

Elite Health Systems Inc (EHSI) Fair Value & Analysis

Healthcare · US · Market cap $25.7M

EH Elite Health Systems Inc logo Elite Health Systems Inc EHSI · US
Price$0.9000
Fair Value$0.1100
Upside-87.8%
Quality19/100
Watch Elite Health Systems Inc for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.0% net margin
negative free cash flow
Trails peers (0/9)
Narrow moat 5/100
Evidence: Low Range $0.0700 – $0.1400 Share as image

Fair value as of: Aug 17, 2026

From 1 valuation models · updated today

Share price −6.3% over the past month.

Below-average quality, and screening another 88% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case ($0.1400). The favourable scenario is already priced in.
  • Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range ($0.0700 to $0.1400) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$1.90 $0.0400 Fair Value $0.1100 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.

How to read this chart

60‑month range $0.0400 – $1.90 · fair‑value band $0.0700 – $0.1400 · the $0.9000 price screens above the $0.1100 fair value. Dashed = 300-day average. As of Aug 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Elite Health Systems Inc (EHSI) currently trades at $0.9000, while our model-based Fair Value estimate is $0.1100, implying the stock looks roughly 87.8% overvalued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at $2.4M. Fundamentals as of Aug 17, 2026

Our scenario range runs from $0.0700 (bear case) to $0.1400 (bull case); at $0.9000, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -88%, EHSI screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0900 $0.1200 $0.1900 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0900 $0.1200 $0.1900 50

Notify me when EHSI reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $2.4M
Return on equity -209%
Free cash flow −$4.0M FY2025
Operating margin -92.9%
EPS (TTM) $-0.3800

Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 19/100

Of which business quality 27 · Market factors (momentum, volatility) 22

Profitability 1
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 10
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Elite Health Systems Inc., through its subsidiaries, develops a business to provide Medicare Advantage plans and other healthcare related services in California and Nevada. The company also focuses on improving and providing access to healthcare, primarily for seniors and special needs groups. The company was formerly known as U.S.

Full company description

Elite Health Systems Inc., through its subsidiaries, develops a business to provide Medicare Advantage plans and other healthcare related services in California and Nevada. The company also focuses on improving and providing access to healthcare, primarily for seniors and special needs groups. The company was formerly known as U.S. NeuroSurgical Holdings, Inc. and changed its name to Elite Health Systems Inc. in September 2024. Elite Health Systems Inc. was founded in 1993 and is headquartered in Ontario, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Elite Health Systems Inc reported revenue of $1.0M in FY2025 versus $1.1M in FY2021, a compound −0.9%/yr. Reported net income was −$7.8M in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
$1.0M
Avg. growth/yr (18Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.4%
Revenue −0.9%/yr
FY21 $1.1M
FY22 $0
FY23 $0
FY24 $0
FY25 $1.0M
Net income
FY21 −$881K
FY22 −$1.3M
FY23 −$816K
FY24 −$2.1M
FY25 −$7.8M

EHSI screens 88% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Elite Health Systems Inc Fair Value". https://www.fairvalue-calculator.com/stock/EHSI

Peer Group

Medical Care Facilities · 266 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 27 · Bottom 25%
Fair Value upside −88% · Bottom 25%
Return on assets -60% · Bottom 25%
Net margin (TTM) 0% · Below median
Operating margin (TTM) -93% · Bottom 25%
Revenue growth 0% · Below median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 4.83× · Pricier than 75% of peers
P/S (TTM) 10.60× · Pricier than 75% of peers

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).

Compare Elite Health Systems Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Elite Health Systems Inc (EHSI) overvalued or undervalued?
As of Aug 17, 2026, our model estimates a fair value of $0.1100 versus a price of $0.9000, about −88% (overvalued).
What is the fair value of EHSI?
Our model-based fair value for Elite Health Systems Inc is $0.1100 (as of Aug 17, 2026), built from audited fundamentals. The current price is $0.9000.
What is the quality score of EHSI?
Elite Health Systems Inc has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Elite Health Systems Inc (EHSI)?
Elite Health Systems Inc reported trailing-twelve-month revenue of about $2.4M (latest available figure, as of Aug 17, 2026).
What is the net profit margin of EHSI?
The net profit margin of Elite Health Systems Inc is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Elite Health Systems Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.